Orexo: Zubsolv Rx Data week 48

According to latest Symphony Health Solutions Rx data, Zubsolv tablets showed a market share of 6.03% (6.06%), 4-week rolling average. The total number of Zubsolv tablets sold week 48 (47) reaching 347,959 (318,968). Zubsolv prescriptions (TRx) recorded a market share of 6.07% (6.10%), 4-week rolling average. Total number of prescriptions reaching 12,413 (11,491) during the week.

The overall market (buprenorphine/naloxone products) showed a y/y growth rate of 7.3% (7.4%) (4-week rolling average unit sales). TRx showed a y/y growth rate by 6.3% (6.4%) (4-week rolling average).

Författaren ägde vid analystillfället aktier i bolaget.

Fler bolagsanalyser

Här listas fler bolagsanalyser ifrån Redeyes analysavdelning.

Publicerad Rubrik Analystyp
2017-03-24 Update
2017-03-22 Analys
2017-03-21 Update
2017-03-21 Update
2017-03-17 Update
2017-03-16 Update
2017-03-14 Update
2017-03-14 Update
2017-03-10 Update
2017-03-10 Update
2017-03-07 Update
2017-03-07 Update
2017-03-07 Update
2017-03-07 Update
2017-03-06 Update
2017-03-06 Update
2017-03-03 Update
2017-03-03 Update
2017-03-03 Update
2017-03-03 Update
2017-03-01 Update
2017-02-28 Update
2017-02-27 Update
2017-02-27 Update
2017-02-27 Update